Prospective evaluation of two specific IgG immunoassays (HemosIL


Journal

International journal of laboratory hematology
ISSN: 1751-553X
Titre abrégé: Int J Lab Hematol
Pays: England
ID NLM: 101300213

Informations de publication

Date de publication:
Jun 2021
Historique:
revised: 30 09 2020
received: 13 08 2020
accepted: 21 10 2020
pubmed: 28 11 2020
medline: 16 6 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

The accurate diagnosis of heparin-induced thrombocytopenia (HIT) is essential to ensure adequate treatment and prevent complications. First step diagnosis test are immunoassays including enzyme-linked immunosorbent assays (ELISAs) and rapid immunoassays. Using a Bayesian approach, we prospectively evaluated the performance of the IgG PF4/polyvinylsulfonate ELISA and a chemiluminescent immunoassay (CLIA), which are specific for IgG and use the same antigenic target to detect HIT antibodies. One hundred and eighty-four 184 consecutive patients with an intermediate (n = 159) or high (n = 25) clinical pretest probability of HIT based on the 4Ts score or platelet pattern were included. Both immunoassays (IAs) were performed on all 184 samples, and definite HIT was confirmed with a positive serotonin release assay in 29 patients (12.7%). The sensitivity (Ss) and negative predictive value (NPV) of ELISA were excellent (100%) allowing HIT to be excluded with good confidence when the test was negative. In addition, the Ss and NPV of the CLIA equalled 93.1% and 98.6%, respectively, as it was negative in two definite HIT. When the CLIA was negative, the post-test probability of HIT was 0.7% in case of intermediate risk. Although there was excellent agreement between CLIA and ELISA results, the quantitative values provided by the two IAs were not correlated. AcuStar HIT

Identifiants

pubmed: 33244896
doi: 10.1111/ijlh.13404
doi:

Substances chimiques

Anticoagulants 0
Immunoglobulin G 0
Heparin 9005-49-6

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

468-476

Subventions

Organisme : Institut pour la Recherche sur la Thrombose et l'Hémostase (IRTH)

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(19):1883-1884.
Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation. 1999;99(19):2530-2536.
Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708.
Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol. 1989;73(2):235-240.
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167.
Gruel Y, De Maistre E, Pouplard C, et al. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med. 2020;39(2):291-310.
Vayne C, Guery E-A, Gruel Y, Pouplard C. Données actualisées sur les thrombopénies induites par l’héparine. RFL. 2017;2017(494):41-53.
Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol. 2005;128(6):837-841.
Vayne C, May MA, Bourguignon T, et al. frequency and clinical impact of platelet factor 4-specific antibodies in patients undergoing extracorporeal membrane oxygenation. Thromb Haemost. 2019;119(7):1138-1146.
Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg. 2011;213(1):10-17.
Leroux D, Hezard N, Lebreton A, et al. Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert® HIT) for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2014;166(5):774-782.
Pouplard C, Gueret P, Fouassier M, et al. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2007;5(7):1373-1379.
Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab(PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. Thromb Res. 2017;153:108-117.
Jourdy Y, Nougier C, Rugeri L, Bordet JC, Sobas F, Negrier C. Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol. 2015;37(2):244-252.
Sun L, Gimotty PA, Lakshmanan S, Cuker A. Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia. A systematic review and meta-analysis. Thromb Haemost. 2016;115(5):1044-1055.
Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A. Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(6):1203-1212.
Pouplard C, Leroux D, Regina S, Rollin J, Gruel Y. Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost. 2010;103(1):145-150.
Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2016;127(5):546-557.
Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost. 2008;6(8):1304-1312.
Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost. 2014;40(1):106-114.
Marchetti M, Barelli S, Zermatten MG, et al. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia. Blood. 2020;135(14):1171-1184.
Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood. 2018;132(12):1345-1349.
Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S.
Pouplard C, Amiral J, Borg JY, Vissac AM, Delahousse B, Gruel Y. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol. 1997;99(2):273-280.
Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30.
Vayne C, Guery EA, Kizlik-Masson C, et al. Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies. Br J Haematol. 2017;179(5):811-819.
Fagan TJ. Letter: Nomogram for Bayes theorem. N Engl J Med. 1975;293(5):257.
Tardy B, Lecompte T, Mullier F, Vayne C, Pouplard C. Detection of platelet-activating antibodies associated with heparin-induced thrombocytopenia. J Clin Med. 2020;9(4):1226-1251.
Legnani C, Cini M, Pili C, Boggian O, Frascaro M, Palareti G. Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia. Thromb Haemost. 2010;104(2):402-409.
Nellen V, Sulzer I, Barizzi G, Lämmle B, Alberio L. Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients. Haematologica. 2012;97(1):89-97.
Nguyen TH, Greinacher A. Distinct binding characteristics of Pathogenic anti-platelet factor-4/polyanion antibodies to antigens coated on different substrates: a perspective on clinical application. ACS Nano. 2018;12(12):12030-12041.
Althaus K, Hron G, Strobel U, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. Thromb Res. 2013;131(3):e85-90.
Favaloro EJ, McCaughan G, Mohammed S, et al. HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia. Pathology. 2018;50(4):426-436.
Vianello F, Sambado L, Scarparo P, et al. Comparison of three different immunoassays in the diagnosis of heparin-induced thrombocytopenia. Clin Chem Lab Med. 2015;53(2):257-263.
Bankova A, Andres Y, Horn MP, Alberio L, Nagler M. Rapid immunoassays for diagnosis of heparin-induced thrombocytopenia: Comparison of diagnostic accuracy, reproducibility, and costs in clinical practice. PLoS One. 2017;12(6):e0178289.
Minet V, Bailly N, Douxfils J, et al. Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study. Thromb Res. 2013;132(3):352-359.
Van Hoecke F, Devreese K. Evaluation of two new automated chemiluminescent assays (HemosIL® AcuStar HIT-IgG and HemosIL(R) AcuStar HIT-Ab) for the detection of heparin-induced antibodies in the diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol. 2012;34(4):410-416.
Nguyen TH, Greinacher A. Effect of pH and ionic strength on the binding strength of anti-PF4/polyanion antibodies. Eur Biophys J. 2017;46(8):795-801.
Warkentin TE, Sheppard JI, Smith JW, et al. Combination of two complementary automated rapid assays for diagnosis of heparin-induced thrombocytopenia (HIT). J Thromb Haemost. 2020;18(6):1435-1446.

Auteurs

Emilie Jousselme (E)

Department of Haematology-Haemostasis, Civil Hospices of Lyon, Bron, France.

Eve-Anne Guéry (EA)

Department of Haematology-Haemostasis, Regional University Hospital of Tours, Tours, France.

Christophe Nougier (C)

Department of Haematology-Haemostasis, Civil Hospices of Lyon, Bron, France.

Frédéric Sobas (F)

Department of Haematology-Haemostasis, Civil Hospices of Lyon, Bron, France.

Jérôme Rollin (J)

Department of Haematology-Haemostasis, Regional University Hospital of Tours, Tours, France.
EA 7501 GICC, University of Tours, Tours, France.

Yves Gruel (Y)

Department of Haematology-Haemostasis, Regional University Hospital of Tours, Tours, France.
EA 7501 GICC, University of Tours, Tours, France.

Caroline Vayne (C)

Department of Haematology-Haemostasis, Regional University Hospital of Tours, Tours, France.
EA 7501 GICC, University of Tours, Tours, France.

Claire Pouplard (C)

Department of Haematology-Haemostasis, Regional University Hospital of Tours, Tours, France.
EA 7501 GICC, University of Tours, Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH